Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2
Randomisation between 3 courses of neoadjuvant Carboplatin plus Paclitaxel or no
chemotherapy before surgery.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Jens B. Sorensen, MD
Dept. Oncology, Rigshospitalet
Denmark: National Board of Health
Neoadjuvant treatment in NSCLC